



October 8th, 2019

Nihon Servier Co., Ltd.

Yakult Honsha Co., Ltd.

Nihon Servier and Yakult Honsha Enter Into a Promotion Agreement for Liposomal Irinotecan in Japan

Nihon Servier Co., Ltd. (Tokyo, Japan; General Manager and Representative Director, Eric Delarge: “Nihon Servier”), subsidiary of Servier Group in Japan, and Yakult Honsha Co., Ltd. (Tokyo, Japan; President and Representative Director, Takashige Negishi; “Yakult”) signed an agreement for the promotion of liposomal irinotecan in Japan, which is currently under regulatory review in the country.

Under the terms of this agreement, Yakult has exclusive promotion rights for the territory of Japan and Nihon Servier which will hold the marketing authorization for liposomal irinotecan retains the option of copromotion.

Liposomal irinotecan is an encapsulated formulation of irinotecan. Liposomal irinotecan is currently marketed in more than 17 countries worldwide for the treatment of adult patients with pancreatic cancer, who have progressed following gemcitabine-based therapy, in combination therapy with fluorouracil (5-FU) and leucovorin (LV)¹, under the brand name Onivyde[®].

Nihon Servier filed a NDA of liposomal irinotecan in Japan in March 2019 for the indication of metastatic pancreatic cancer after disease progression following prior gemcitabine-based therapy. Yakult positions pancreatic cancer as one of the most important disease areas, and will carry out promotion activities for liposomal irinotecan with its expertise and network in Japan.

According to Eric Delarge, Representative Director and General Manager of Nihon Servier, *“The arrival of liposomal irinotecan on the Japanese market constitutes an important medical treatment contribution for patients for whom therapeutic alternatives are still limited. Through this partnership based on Yakult’s long-term presence in oncology specialty and its experience in pancreatic cancer, Servier is significantly strengthening its visibility in Japan and the Group’s geographical footprint across the world.”*

According to Masanori Ito, Director, Managing Executive Officer and Head of Pharmaceutical Business Division of Yakult, *“We are delighted to conclude the agreement for the promotion of liposomal irinotecan in Japan with Nihon Servier. Yakult is known as the inventor of irinotecan, the active pharmaceutical ingredient of liposomal irinotecan. We hope our existing capability and expertise will contribute to the proper use of liposomal irinotecan for the treatment of patients with pancreatic cancer, a disease with limited treatment options, upon launch.”*

In 2017, pancreatic cancer was the fourth leading cause of cancer-related deaths in Japan, accounting for 9.2% of total deaths caused by cancerⁱⁱ. There is a medical need for the treatment of pancreatic cancer, because of the limited therapeutic options for these patients.

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) in research and development. Corporate growth is driven by Servier’s constant search for innovation in

five areas of excellence: cardiovascular, immuno-inflammatory and neurodegenerative diseases, oncology and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. One hundred million patients are treated daily worldwide with Servier drugs. Becoming a key player in oncology is part of Servier's long-term strategy. Currently, there are twelve molecular entities in clinical development in this area, targeting gastro-intestinal and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, immune targeted therapies, to deliver life-changing medicines to patients. More information: www.servier.com

In Japan, Nihon Servier was established in 1981. Servier products have been marketed through local partners in Japan. More information: www.nihonservier.co.jp

About Yakult

Yakult Honsha is a leading Japanese company focused on the development and marketing of pharmaceuticals, foods, beverages, and cosmetics under the corporate philosophy "We contribute to the health and happiness of people around the world through pursuit of excellence in life science". As for pharmaceutical business, Yakult Honsha has an emerging presence in oncology through the development and marketing of anti-tumor agents including Campto® and Elplat®. For more information on Yakult, visit the company's website: <https://www.yakult.co.jp/english>

ⁱ Liposomal irinotecan. Summary of the European Public Assessment Report.

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/004125/WC500215029.pdf. Published October 25, 2016. Updated July 12, 2017.

ⁱⁱ Foundation for Promotion of Cancer Research; Cancer Statistics in Japan-2018